Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 222

1.

A Genomic Classifier for Predicting Clinically Aggressive Luminal Bladder Tumors with Higher Rates of Pathological Upstaging.

de Jong JJ, Liu Y, Boorjian SA, Bivalacqua TJ, Porten SP, Wheeler T, Davicioni E, Svatek RS, Boormans JL, Black PC, Lotan Y, Gibb EA.

J Urol. 2020 Feb 14:101097JU0000000000000798. doi: 10.1097/JU.0000000000000798. [Epub ahead of print]

PMID:
32074006
2.

Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer.

D'Andrea D, Black PC, Zargar H, Zargar-Shoshtari K, Zehetmayer S, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Shariat SF.

Urol Oncol. 2020 Feb 11. pii: S1078-1439(20)30011-9. doi: 10.1016/j.urolonc.2020.01.010. [Epub ahead of print]

PMID:
32057595
3.

Kdm6a deficiency activates inflammatory pathways, promotes M2 macrophage polarization, and causes bladder cancer in cooperation with p53 dysfunction.

Kobatake K, Ikeda K, Nakata Y, Yamasaki N, Ueda T, Kanai A, Sentani K, Sera Y, Hayashi T, Koizumi M, Miyakawa Y, Inaba T, Sotomaru Y, Kaminuma O, Ichinohe T, Honda ZI, Yasui W, Horie S, Black PC, Matsubara A, Honda H.

Clin Cancer Res. 2020 Feb 11. pii: clincanres.2230.2019. doi: 10.1158/1078-0432.CCR-19-2230. [Epub ahead of print]

PMID:
32047002
4.

Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol. In press.

Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS, Al-Ahmadie H, Choi W, Castro MAA, Fontugne J, Eriksson P, Mo Q, Kardos J, Zlotta A, Hartmann A, Dinney CP, Bellmunt J, Powles T, Malats N, Chan KS, Kim WY, McConkey DJ, Black PC, Dyrskjøt L, Höglund M, Lerner SP, Real FX, Radvanyi F, Aine M, Bernard-Pierrot I, Czerniak B, Gibb EA, Kim J, Kwiatkowski DJ, Lebret T, Liedberg F, Siefker-Radtke AA, Sirab N, Taber A, Weinstein JN.

Eur Urol. 2020 Feb 6. pii: S0302-2838(19)30958-3. doi: 10.1016/j.eururo.2019.12.014. [Epub ahead of print] No abstract available.

PMID:
32037144
5.

Re: Clinical Efficacy and Biomarker Analysis of Neoadjuvant Atezolizumab in Operable Urothelial Carcinoma in the ABACUS Trial.

Schulz GB, Black PC.

Eur Urol. 2020 Feb 3. pii: S0302-2838(20)30055-5. doi: 10.1016/j.eururo.2020.01.019. [Epub ahead of print] No abstract available.

PMID:
32029339
6.

Framing Pragmatic Strategies to Reduce Mortality From Bladder Cancer: An Endorsement From the Society of Urologic Oncology.

de Vere White R, Lara PN Jr, Black PC, Evans CP, Dall'Era M.

J Clin Oncol. 2020 Jan 17:JCO1901731. doi: 10.1200/JCO.19.01731. [Epub ahead of print] No abstract available.

PMID:
31951493
7.

Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy.

Grivas P, Bismar TA, Alva AS, Huang HC, Liu Y, Seiler R, Alimohamed N, Cheng L, Hyndman ME, Dabbas B, Black PC, Davicioni E, Wright JL, Ornstein MC, Mian OY, Kaimakliotis HZ, Gibb EA, Lotan Y.

Urol Oncol. 2019 Dec 4. pii: S1078-1439(19)30459-4. doi: 10.1016/j.urolonc.2019.11.004. [Epub ahead of print]

PMID:
31812633
8.

Incidentalomas of the prostate detected by 18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography.

Mannas MP, Lee T, Pourghiasian M, Wilson D, Black PC.

Can Urol Assoc J. 2019 Nov 29. doi: 10.5489/cuaj.5976. [Epub ahead of print]

PMID:
31793859
9.

Re: Aurélie Kamoun, Aurélien de Reyniès, Yves Allory, et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.09.006: A Statement from the International Bladder Cancer Network.

Williams SB, Black PC, Dyrskjøt L, Seiler R, Schmitz-Dräger B, Nawroth R, Todenhöfer T, Kamat AM, Goebell PJ.

Eur Urol. 2019 Nov 28. pii: S0302-2838(19)30874-7. doi: 10.1016/j.eururo.2019.11.011. [Epub ahead of print] No abstract available.

PMID:
31787429
10.

EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort: Under the Auspices of the EAU-ESMO Guidelines Committees.

Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Der Kwast TV, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, De Bari B, De Blok W, J L De Visschere P, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, Müller AC, Müller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, J G Oyen W, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Der Heijden AGV, Van Poppel H, Vartolomei MD, Veskimäe E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Williams A, Zigeuner R, Horwich A.

Eur Urol. 2020 Feb;77(2):223-250. doi: 10.1016/j.eururo.2019.09.035. Epub 2019 Nov 19.

PMID:
31753752
11.

EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†.

Horwich A, Babjuk M, Bellmunt J, Bruins HM, Reijke TM, Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Kwast TV, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, Bari B, Blok W, De Visschere PJL, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, Müller AC, Müller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, Oyen WJG, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Van Der Heijden AG, Van Poppel H, Vartolomei MD, Veskimäe E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Williams A, Zigeuner R, Witjes JA.

Ann Oncol. 2019 Nov 1;30(11):1697-1727. doi: 10.1093/annonc/mdz296.

PMID:
31740927
12.

A partial augmented reality system with live ultrasound and registered preoperative MRI for guiding robot-assisted radical prostatectomy.

Samei G, Tsang K, Kesch C, Lobo J, Hor S, Mohareri O, Chang S, Goldenberg SL, Black PC, Salcudean S.

Med Image Anal. 2020 Feb;60:101588. doi: 10.1016/j.media.2019.101588. Epub 2019 Oct 29.

PMID:
31739281
13.

Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials.

Kates M, Matoso A, Choi W, Baras AS, Daniels MJ, Lombardo K, Brant A, Mikkilineni N, McConkey DJ, Kamat AM, Svatek RS, Porten SP, Meeks JJ, Lerner SP, Dinney CP, Black PC, McKiernan JM, Anderson C, Drake CG, Bivalacqua TJ.

Clin Cancer Res. 2020 Feb 15;26(4):882-891. doi: 10.1158/1078-0432.CCR-19-1920. Epub 2019 Nov 11.

PMID:
31712383
14.

The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy.

Black AJ, Zargar H, Zargar-Shoshtari K, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Griffin J, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, McGrath JS, Aning J, Shariat SF, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Spiess PE, Daneshmand S, Sridhar SS, Black PC.

Urol Oncol. 2020 Jan;38(1):3.e17-3.e27. doi: 10.1016/j.urolonc.2019.09.023. Epub 2019 Oct 31.

PMID:
31676278
15.

Discovering Therapeutic Protein Targets for Bladder Cancer Using Proteomic Data Analysis

Bahrami S, Kazemi B, Zali H, Black PC, Basiri A, Bandehpour M, Hedayati M, Sahebkar A.

Curr Mol Pharmacol. 2019 Oct 16. doi: 10.2174/1874467212666191016124935. [Epub ahead of print]

PMID:
31622214
16.

Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis.

de Jong JJ, Liu Y, Robertson AG, Seiler R, Groeneveld CS, van der Heijden MS, Wright JL, Douglas J, Dall'Era M, Crabb SJ, van Rhijn BWG, van Kessel KEM, Davicioni E, Castro MAA, Lotan Y, Zwarthoff EC, Black PC, Boormans JL, Gibb EA.

Genome Med. 2019 Oct 17;11(1):60. doi: 10.1186/s13073-019-0669-z.

17.

Deep Learning-Based Gleason Grading of Prostate Cancer from Histopathology Images - Role of Multiscale Decision Aggregation and Data Augmentation.

Karimi D, Nir G, Fazli L, Black PC, Goldenberg L, Salcudean SE.

IEEE J Biomed Health Inform. 2019 Sep 30. doi: 10.1109/JBHI.2019.2944643. [Epub ahead of print]

PMID:
31567104
18.

A Consensus Molecular Classification of Muscle-invasive Bladder Cancer.

Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS, Al-Ahmadie H, Choi W, Castro MAA, Fontugne J, Eriksson P, Mo Q, Kardos J, Zlotta A, Hartmann A, Dinney CP, Bellmunt J, Powles T, Malats N, Chan KS, Kim WY, McConkey DJ, Black PC, Dyrskjøt L, Höglund M, Lerner SP, Real FX, Radvanyi F; Bladder Cancer Molecular Taxonomy Group.

Eur Urol. 2019 Sep 26. pii: S0302-2838(19)30695-5. doi: 10.1016/j.eururo.2019.09.006. [Epub ahead of print]

19.

Developing a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression Across the Germ Cell Malignancy Spectrum.

Nappi L, Thi M, Lum A, Huntsman D, Eigl BJ, Martin C, O'Neil B, Maughan BL, Chi K, So A, Black PC, Gleave M, Wyatt AW, Lavoie JM, Khalaf D, Bell R, Daneshmand S, Hamilton RJ, Leao RRN, Nichols C, Kollmannsberger C.

J Clin Oncol. 2019 Nov 20;37(33):3090-3098. doi: 10.1200/JCO.18.02057. Epub 2019 Sep 25.

PMID:
31553692
20.

Multicenter Validation of Histopathologic Tumor Regression Grade After Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma.

Voskuilen CS, Oo HZ, Genitsch V, Smit LA, Vidal A, Meneses M, Necchi A, Colecchia M, Xylinas E, Fontugne J, Sibony M, Rouprêt M, Lenfant L, Côté JF, Buser L, Saba K, Furrer MA, van der Heijden MS, Daugaard M, Black PC, van Rhijn BWG, Hendricksen K, Poyet C, Seiler R.

Am J Surg Pathol. 2019 Dec;43(12):1600-1610. doi: 10.1097/PAS.0000000000001371.

PMID:
31524642
21.

Predicting complications following radical cystectomy with the ACS NSQIP universal surgical risk calculator.

Mannas MP, Lee T, Forbes CM, Hong T, Bisaillon A, Gleave ME, So AI, Mayson K, Black PC.

World J Urol. 2019 Aug 27. doi: 10.1007/s00345-019-02915-3. [Epub ahead of print]

PMID:
31456016
22.

Editorial: Bladder cancer within the focus of basic and clinical research. Sixth IBCN Seminars Series.

Seiler R, Black PC, Williams SB, Goebell PJ, Kamat AM, Nawroth R, Schmitz-Dräger BJ.

Urol Oncol. 2019 Nov;37(11):815-817. doi: 10.1016/j.urolonc.2019.06.025. Epub 2019 Jul 31. Review. No abstract available.

PMID:
31377169
23.

Hope, hype and biology: the current biomarker landscape in bladder cancer.

Black PC.

World J Urol. 2019 Sep;37(9):1739-1740. doi: 10.1007/s00345-019-02885-6. Epub 2019 Jul 27. No abstract available.

PMID:
31352566
24.

Can Biomarkers Guide the Use of Neoadjuvant Chemotherapy in T2 Bladder Cancer?

Grossman HB, Bellmunt J, Black PC.

Eur Urol Oncol. 2019 Sep;2(5):597-602. doi: 10.1016/j.euo.2019.06.002. Epub 2019 Jul 4.

25.

Author Correction: Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer.

Korpal M, Puyang X, Wu ZJ, Seiler R, Furman C, Oo HZ, Seiler M, Irwin S, Subramanian V, Joshi JJ, Wang CK, Rimkunas V, Tortora D, Yang H, Kumar N, Kuznetsov G, Matijevic M, Chow J, Kumar P, Zou J, Feala J, Corson L, Henry R, Selvaraj A, Davis A, Bloudoff K, Douglas J, Kiss B, Roberts M, Fazli L, Black PC, Fekkes P, Smith PG, Warmuth M, Yu L, Hao MH, Larsen N, Daugaard M, Zhu P.

Nat Commun. 2019 Jun 4;10(1):2527. doi: 10.1038/s41467-019-10666-3.

26.

Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review.

Lotan Y, Black PC, Caba L, Chang SS, Cookson MS, Daneshmand S, Kamat AM, McKiernan JM, Pruthi RS, Ritch CR, Steinberg GD, Svatek RS, Zwarthoff EC.

Eur Urol Oncol. 2018 Aug;1(3):223-230. doi: 10.1016/j.euo.2018.04.010. Epub 2018 May 15. Review.

PMID:
31102625
27.

Development and Acceptability Testing of a Patient Decision Aid for Urinary Diversion with Radical Cystectomy.

McAlpine K, Lavallée LT, Stacey D, Moodley P, Cagiannos I, Morash C, Black PC, Kulkarni GS, Shayegan B, Kassouf W, Siemens R, So A, Leveridge MJ, Boorjian SA, Daneshmand S, Smith AB, Power N, Izawa J, Drachenberg DE, Fairey A, Rendon RA, Breau RH.

J Urol. 2019 Nov;202(5):1001-1007. doi: 10.1097/JU.0000000000000341. Epub 2019 Oct 9.

PMID:
31099720
28.

Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors.

Lotan Y, Boorjian SA, Zhang J, Bivalacqua TJ, Porten SP, Wheeler T, Lerner SP, Hutchinson R, Francis F, Davicioni E, Svatek RS, Chen CL, Black PC, Gibb EA.

Eur Urol. 2019 Aug;76(2):200-206. doi: 10.1016/j.eururo.2019.04.036. Epub 2019 May 12.

PMID:
31092337
29.

Molecular landscape of carcinoma invading bladder muscle: does patient age matter?

Seiler R, Wyatt AW, Black PC.

BJU Int. 2019 Nov;124(5):719-721. doi: 10.1111/bju.14802. Epub 2019 Jun 24. No abstract available.

PMID:
31074172
30.

Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma.

Warren M, Kolinsky M, Canil CM, Czaykowski P, Sridhar SS, Black PC, Booth CM, Kassouf W, Eapen L, Mukherjee SD, Blais N, Eigl BJ, Winquist E, Basappa NS, North SA; GUMOC.

Can Urol Assoc J. 2019 Apr 26:318-327. doi: 10.5489/cuaj.6015. [Epub ahead of print] No abstract available.

31.

Emerging Immunotherapy Options for bacillus Calmette-Guérin Unresponsive Nonmuscle Invasive Bladder Cancer.

Meng MV, Gschwend JE, Shore N, Grossfeld GD, Mostafid H, Black PC.

J Urol. 2019 Dec;202(6):1111-1119. doi: 10.1097/JU.0000000000000297. Epub 2019 May 1. Review.

PMID:
31042108
32.

Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder Cancer.

Williams SB, Hudgins HK, Ray-Zack MD, Chamie K, Smaldone MC, Boorjian SA, Daneshmand S, Black PC, Kamat AM, Goebell PJ, Seiler R, Schmitz-Drager B, Nawroth R, Baillargeon J, Klaassen Z, Kulkarni GS, Kim SP, Lee EK, Holzbeierlein JM, Hollenbeck BK, Gore JL.

Eur Urol Oncol. 2019 Mar;2(2):119-125. doi: 10.1016/j.euo.2018.07.006. Epub 2018 Aug 14.

PMID:
31017086
33.

Molecular Characterization of Neuroendocrine-like Bladder Cancer.

Batista da Costa J, Gibb EA, Bivalacqua TJ, Liu Y, Oo HZ, Miyamoto DT, Alshalalfa M, Davicioni E, Wright J, Dall'Era MA, Douglas J, Boormans JL, Van der Heijden MS, Wu CL, van Rhijn BWG, Gupta S, Grivas P, Mouw KW, Murugan P, Fazli L, Ra S, Konety BR, Seiler R, Daneshmand S, Mian OY, Efstathiou JA, Lotan Y, Black PC.

Clin Cancer Res. 2019 Jul 1;25(13):3908-3920. doi: 10.1158/1078-0432.CCR-18-3558. Epub 2019 Apr 5.

PMID:
30952638
34.

New horizons in bladder cancer research.

Boormans JL, Zwarthoff EC, Black PC, Goebell PJ, Kamat AM, Nawroth R, Seiler R, Williams SB, Schmitz-Dräger BJ.

Urol Oncol. 2019 Mar 7. pii: S1078-1439(18)30508-8. doi: 10.1016/j.urolonc.2018.12.014. [Epub ahead of print] Review.

PMID:
30852032
35.

Comparison of Artificial Intelligence Techniques to Evaluate Performance of a Classifier for Automatic Grading of Prostate Cancer From Digitized Histopathologic Images.

Nir G, Karimi D, Goldenberg SL, Fazli L, Skinnider BF, Tavassoli P, Turbin D, Villamil CF, Wang G, Thompson DJS, Black PC, Salcudean SE.

JAMA Netw Open. 2019 Mar 1;2(3):e190442. doi: 10.1001/jamanetworkopen.2019.0442.

36.

Canadian Urological Association guideline: Muscle-invasive bladder cancer.

Kulkarni GS, Black PC, Sridhar SS, Kapoor A, Zlotta AR, Shayegan B, Rendon RA, Chung P, van der Kwast T, Alimohamed N, Fradet Y, Kassouf W.

Can Urol Assoc J. 2019 Jan 31:230-238. doi: 10.5489/cuaj.5902. [Epub ahead of print] No abstract available.

37.

Predictive Biomarkers for Checkpoint Blockade in Urothelial Cancer: A Systematic Review.

Lavoie JM, Black PC, Eigl BJ.

J Urol. 2019 Jul;202(1):49-56. doi: 10.1097/JU.0000000000000136. Epub 2019 Jun 7.

PMID:
30730407
38.

Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.

Efstathiou JA, Mouw KW, Gibb EA, Liu Y, Wu CL, Drumm MR, da Costa JB, du Plessis M, Wang NQ, Davicioni E, Feng FY, Seiler R, Black PC, Shipley WU, Miyamoto DT.

Eur Urol. 2019 Jul;76(1):59-68. doi: 10.1016/j.eururo.2019.01.011. Epub 2019 Feb 1.

PMID:
30712971
39.

Editorial: Basic research in bladder cancer - refining the tools. 3rd IBCN seminars series1.

Black PC, Goebell PJ, Kamat AM, Nawroth R, Seiler R, Williams SB, Schmitz-Dräger BJ.

Urol Oncol. 2019 Jan 22. pii: S1078-1439(19)30003-1. doi: 10.1016/j.urolonc.2019.01.003. [Epub ahead of print] Review.

PMID:
30683454
40.

Global, Regional and National Burden of Bladder Cancer, 1990 to 2016: Results from the GBD Study 2016.

Ebrahimi H, Amini E, Pishgar F, Moghaddam SS, Nabavizadeh B, Rostamabadi Y, Aminorroaya A, Fitzmaurice C, Farzadfar F, Nowroozi MR, Black PC, Daneshmand S.

J Urol. 2019 May;201(5):893-901. doi: 10.1097/JU.0000000000000025.

PMID:
30676477
41.

Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.

Vandekerkhove G, Struss WJ, Annala M, Kallio HML, Khalaf D, Warner EW, Herberts C, Ritch E, Beja K, Loktionova Y, Hurtado-Coll A, Fazli L, So A, Black PC, Nykter M, Tammela T, Chi KN, Gleave ME, Wyatt AW.

Eur Urol. 2019 Apr;75(4):667-675. doi: 10.1016/j.eururo.2018.12.042. Epub 2019 Jan 10.

PMID:
30638634
42.

Comparing diagnostic accuracy of luminal water imaging with diffusion-weighted and dynamic contrast-enhanced MRI in prostate cancer: A quantitative MRI study.

Sabouri S, Chang SD, Goldenberg SL, Savdie R, Jones EC, Black PC, Fazli L, Kozlowski P.

NMR Biomed. 2019 Feb;32(2):e4048. doi: 10.1002/nbm.4048. Epub 2018 Dec 21.

PMID:
30575145
43.

Urothelial Carcinoma in Bladder Diverticula: A Multicenter Analysis of Characteristics and Clinical Outcomes.

Voskuilen CS, Seiler R, Rink M, Poyet C, Noon AP, Roghmann F, Necchi A, Aziz A, Lavollé A, Young MJ, Marks P, Saba K, van Rhijn BWG, Fransen van de Putte EE, Ablat J, Black PC, Sosnowski R, Dobruch J, Kumar P, Jallad S, Catto JWF, Xylinas E, Hendricksen K; Young Academic Urologists’ Working Group on Urothelial Carcinoma of the European Association of Urology.

Eur Urol Focus. 2018 Dec 14. pii: S2405-4569(18)30382-1. doi: 10.1016/j.euf.2018.12.002. [Epub ahead of print]

PMID:
30559065
44.

Molecular tumor heterogeneity in muscle invasive bladder cancer: Biomarkers, subtypes, and implications for therapy.

da Costa JB, Gibb EA, Nykopp TK, Mannas M, Wyatt AW, Black PC.

Urol Oncol. 2018 Dec 8. pii: S1078-1439(18)30463-0. doi: 10.1016/j.urolonc.2018.11.015. [Epub ahead of print] Review.

PMID:
30528886
45.

Immunology, Immunotherapy, and Translating Basic Science into the Clinic for Bladder Cancer.

Ingersoll MA, Li X, Inman BA, Greiner JW, Black PC, Adam RM.

Bladder Cancer. 2018 Oct 29;4(4):429-440. doi: 10.3233/BLC-180175.

46.

Current Clinical Trials in Non-muscle Invasive Bladder Cancer.

Nykopp TK, Batista da Costa J, Mannas M, Black PC.

Curr Urol Rep. 2018 Oct 24;19(12):101. doi: 10.1007/s11934-018-0852-6. Review.

PMID:
30357541
47.

Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients.

Williams SB, Kamat AM, Chamie K, Froehner M, Wirth MP, Wiklund PN, Black PC, Steinberg GD, Boorjian SA, Daneshmand S, Goebell PJ, Pohar KS, Shariat SF, Thalmann GN.

Eur Urol Oncol. 2018 Jun;1(2):91-100. doi: 10.1016/j.euo.2018.03.005. Epub 2018 Jun 6.

48.

Post-translational modifications in bladder cancer: Expanding the tumor target repertoire.

Oo HZ, Seiler R, Black PC, Daugaard M.

Urol Oncol. 2018 Oct 17. pii: S1078-1439(18)30339-9. doi: 10.1016/j.urolonc.2018.09.001. [Epub ahead of print] Review.

PMID:
30342880
49.

Automatic grading of prostate cancer in digitized histopathology images: Learning from multiple experts.

Nir G, Hor S, Karimi D, Fazli L, Skinnider BF, Tavassoli P, Turbin D, Villamil CF, Wang G, Wilson RS, Iczkowski KA, Lucia MS, Black PC, Abolmaesumi P, Goldenberg SL, Salcudean SE.

Med Image Anal. 2018 Dec;50:167-180. doi: 10.1016/j.media.2018.09.005. Epub 2018 Sep 24.

PMID:
30340027
50.

Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018.

Cumberbatch MGK, Jubber I, Black PC, Esperto F, Figueroa JD, Kamat AM, Kiemeney L, Lotan Y, Pang K, Silverman DT, Znaor A, Catto JWF.

Eur Urol. 2018 Dec;74(6):784-795. doi: 10.1016/j.eururo.2018.09.001. Epub 2018 Sep 26.

Supplemental Content

Loading ...
Support Center